A collaborative data management platform for PROTAC drug discovery

Targeted protein degraders, such as proteolysis targeting chimeras (PROTACs), leverage the cell’s natural ubiquitin-proteasome system to degrade target proteins. Early work has shown that PROTACs can improve the affinity and selectivity of their parent small molecule drugs. Unlike small molecules, each PROTAC molecule can induce degradation of multiple target protein molecules. Therefore, PROTACs can be used at subnanomolar concentrations. However, for PROTACs to work in vivo, they must enter the target cell intact and bind to both the target protein and an E3 ligase to induce ternary complex formation.

In this application note from Collaborative Drug Discovery, Inc. learn more about the CDD Vault^®, a comprehensive data management platform catering to the specific needs of PROTAC drug discovery researchers.